Browse the corpus

Alosetron is a 5-HT3 receptor antagonist that treats severe diarrhea-predominant irritable bowel syndrome (IBS-D). This educational activity focuses on the indications, mechanism of action, and contraindications associated with alosetron. Participants will also review the FDA-issued box warnings, adverse event profiles, toxicity, and critical considerations such as dosing, monitoring, and relevant drug interactions. Understanding alosetron's pharmacological features significantly enhances healthcare professionals' ability to tailor treatment plans to individual patient needs. Reviewing this information can help interprofessional healthcare team members deliver targeted, safe, and personalized care, improving outcomes for patients receiving alosetron therapy. Objectives: Identify the mechanism of action of alosetron. Evaluate the adverse drug reactions associated with alosetron administration. Assess the appropriate monitoring protocols for patients receiving alosetron therapy. Implement effective collaboration and communication among interprofessional team members to improve treatment efficacy and outcomes for patients with IBS-D who might benefit from alosetron therapy. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose During clinical studies, doses up to 16 mg (8 times the recommended daily dose) have been administered without significant adverse reactions. Management of Overdose There is no specific antidote for alosetron.[33] Patients should be managed with appropriate supportive therapy. Overdose with alosetron may reduce the first-pass metabolism of other drugs. A poison control center should be contacted for overdose treatment protocol.

Although studies have shown that alosetron improves IBS-D symptoms, reduces pain and discomfort, and improves patients' quality of life, healthcare providers need to be mindful of the severe adverse effects associated with this medication.[34] Physicians should rule out other GI conditions before prescribing alosetron. Specially trained nurses educate patients, monitor their status, and report issues to the team. Pharmacists review the medication dose and drug-drug interactions and inform patients about potentially dangerous adverse drug reactions. Ischemic colitis and complications of constipation resulting from alosetron use have resulted in hospitalization, surgery, and death. Patients receiving this medication must be monitored closely and advised of the possible symptoms to monitor and prevent severe complications. Nurses can verify patient compliance, monitor for adverse events, document therapeutic responses, and inform clinicians of concerns. Gastroenterologists should be consulted for patients with ischemic colitis or ileus. An umbrella systematic review evaluating pharmacologic treatments for irritable bowel syndrome (IBS) assessed patient outcomes associated with 5-HT-3 antagonists, 5-HT4 agonists, guanylate cyclase-C agonists, antispasmodics, and alosetron. According to the review's findings, alosetron exhibited beneficial effects, including relief of global IBS symptoms.[35] The REMS program for alosetron was implemented to reduce gastrointestinal adverse events. This program restricted the prescribing of alosetron to providers enrolled in the program based on their understanding of the risks versus benefits of the medication.[16] The FDA eliminated the Alosetron REMS program in 2023 based on stable adverse event reporting from its reintroduction in 2002 to 2016, consistent ischemic colitis rates in new patients, and a trend in prescriptions without increased utilization. The prescribing information includes warnings regarding ischemic colitis and complications of constipation. Collaboration between an interprofessional team of clinicians (MDs, DOs, NPs, PAs), specialty-trained nurses, and pharmacists leads to improved patient outcomes.